title: Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma.
abstract: An analysis of other primary cancers in individuals with non-Hodgkin's lymphoma (NHL) can help to elucidate this cancer aetiology. In all, 109 451 first primary NHL were included in a pooled analysis of 13 cancer registries. The observed numbers of second cancers were compared to the expected numbers derived from the age-, sex-, calendar period- and registry-specific incidence rates. We also calculated the standardised incidence ratios for NHL as a second primary after other cancers. There was a 47% (95% confidence interval 43-51%) overall increase in the risk of a primary cancer after NHL. A strongly significant (P<0.001) increase was observed for cancers of the lip, tongue, oropharynx*, stomach, small intestine, colon*, liver, nasal cavity*, lung, soft tissues*, skin melanoma*, nonmelanoma skin*, bladder*, kidney*, thyroid*, Hodgkin's lymphoma*, lymphoid leukaemia* and myeloid leukaemia. Non-Hodgkin's lymphoma as a second primary was increased after cancers marked with an asterisk. Patterns of risk indicate a treatment effect for lung, bladder, stomach, Hodgkin's lymphoma and myeloid leukaemia. Common risk factors may be involved for cancers of the lung, bladder, nasal cavity and for soft tissues, such as pesticides. Bidirectional effects for several cancer sites of potential viral origin argue strongly for a role for immune suppression in NHL.
authors.affiliation: International Agency for Research on Cancer, 69008 Lyon, France. brennan@iarc.fr
authors.forename: P
authors.initials: P
authors.lastname: Brennan
authors.forename: G
authors.initials: G
authors.lastname: Scélo
authors.forename: K
authors.initials: K
authors.lastname: Hemminki
authors.forename: L
authors.initials: L
authors.lastname: Mellemkjaer
authors.forename: E
authors.initials: E
authors.lastname: Tracey
authors.forename: A
authors.initials: A
authors.lastname: Andersen
authors.forename: D H
authors.initials: DH
authors.lastname: Brewster
authors.forename: E
authors.initials: E
authors.lastname: Pukkala
authors.forename: M L
authors.initials: ML
authors.lastname: McBride
authors.forename: E V
authors.initials: EV
authors.lastname: Kliewer
authors.forename: J M
authors.initials: JM
authors.lastname: Tonita
authors.forename: A
authors.initials: A
authors.lastname: Seow
authors.forename: V
authors.initials: V
authors.lastname: Pompe-Kirn
authors.forename: C
authors.initials: C
authors.lastname: Martos
authors.forename: J G
authors.initials: JG
authors.lastname: Jonasson
authors.forename: D
authors.initials: D
authors.lastname: Colin
authors.forename: P
authors.initials: P
authors.lastname: Boffetta
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000150:complications / Q000453:epidemiology*